Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 12/2/2024 | $12.00 | Buy | Citigroup |
| 11/29/2024 | $7.00 → $11.00 | Outperform | Wedbush |
| 10/16/2024 | $15.00 | Outperform | Leerink Partners |
| 3/26/2024 | $22.00 | Buy | Guggenheim |
| 3/19/2024 | $30.00 | Buy | H.C. Wainwright |
| 3/7/2024 | $16.00 | Buy | Citigroup |
| 1/2/2024 | $14.00 | Equal Weight → Overweight | Wells Fargo |
LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com starting at 7:00 a.m. ET on June 17, 2025. The on-demand webcast will be archived on the Compan
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-
S-8 - Voyager Therapeutics, Inc. (0001640266) (Filer)
8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)
SCHEDULE 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)